FOR OFFICIAL USE ONLY

/86668

ACCESS DB # _____

PLEASE PRINT CLEARLY

Scientific and Technical Information Center

SEARCH REQUEST FORM

Requester's Full Name: Gembeh Shirley Examiner #: 70889 Date: 4/22/06

Art Unit: 1614 Phone Number: 2-8504 Serial Number: ~~10/273802~~ 10/152347

Location (Bldg/Room#): _____ (Mailbox #): _____ Results Format Preferred (circle): PAPER DISK

****

To ensure an efficient and quality search, please attach a copy of the cover sheet, claims, and abstract or fill out the following:

Title of Invention: M3 Muscarinic acetylcholine receptor antago.

Inventors (please provide full names): Dramane. I. Laine et al

Earliest Priority Date: 8/6/02

Search Topic:

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc., if known.

For Sequence Searches Only *Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search all species of the claimed compound.

A Quick & dirty search indicates the election of the compound is

(2-4 chloro-thiazol-2-yl) Phenyl] carbamic acid piperidin-4-ylmethyl ester is novel..

See attached claims highlighted compound elected.

Rush Search Approved - Thirtyforth 21 Apr 2006

****

STAFF USE ONLY

Searcher: Beverly c 2528

Searcher Phone #: _____

Searcher Location: _____

Date Searcher Picked Up: _____

Date Completed: _____

Searcher Prep & Review Time: _____

Online Time: _____

Type of Search

_____ NA Sequence (#)

_____ AA Sequence (#)

_____ Structure (#)

_____ Bibliographic

_____ Litigation

_____ Fulltext

_____ Other

Vendors and cost where applicable

✓ STN _____ Dialog

_____ Questel/Orbit _____ Lexis/Nexis

_____ Westlaw _____ WWW/Internet

____ In-house sequence systems

___ Commercial ___ Oligomer ____ Score/Length

___ Interference ___ SPDI ____ Encode/Transl

_____ Other (specify)

Gemboch, S.
10/523478

FILE 'REGISTRY' ENTERED AT 16:53:37 ON 24 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 23 APR 2006 HIGHEST RN 881543-45-9
DICTIONARY FILE UPDATES: 23 APR 2006 HIGHEST RN 881543-45-9

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

L1 STR



Str
Form. I.

REP G1=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 11
ECOUNT IS E3 C E1 N E1 S AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED

Searcher : Shears 571-272-2528

NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE
L2 151 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED 176640 ITERATIONS 151 ANSWERS
SEARCH TIME: 00.00.03

FILE 'CAPLUS' ENTERED AT 16:53:37 ON 24 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 24 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 23 Apr 2006 (20060423/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

L3 4 S L2
L4 2 S L3 NOT (PY=>2002 OR PD=>20020806) ← Restrict to hits dater prior to 08-06-02

E1 THROUGH E2 ASSIGNED

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2000:351518 CAPLUS
DOCUMENT NUMBER: 133:4650
TITLE: Preparation of heteroaryl-substituted aromatic compounds as antiherpes compounds
INVENTOR(S): Simoneau, Bruno; Gaudette, James J.; Faucher, Anne-Marie; Grygon, Christine A.; Hargrave, Karl D.; Thavonekham, Bounkham
PATENT ASSIGNEE(S): Boehringer Ingelheim (Canada) Ltd., Can.
SOURCE: PCT Int. Appl., 157 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000029399	A1	20000525	WO 1999-CA1066	19991109

W: CA, JP, MX, US
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

PRIORITY APPLN. INFO.: US 1998-108272P P 19981112

OTHER SOURCE(S): MARPAT 133:4650

GI



II



III

AB The title compds. X-Aryl-Y-Z [I; X = 5-6 membered aromatic heterocycle; Aryl = (un)substituted Ph, pyridyl; Y is absent or a bridging group, for example NHC(O)CH2; Z is a terminal group, for example NHCO2t-Bu or II], which inhibit the herpes helicase-primase enzyme, rendering the compds. useful as antiviral agents, were prepared E.g., a multi-step synthesis of benzamide III was presented. Biol. data (IC50 and/or EC50 against HSV-1 and HCMV) for compds. I were given.

IT **270566-40-0P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heteroaryl-substituted aromatic compds. as antiherpes compds.)

RN 270566-40-0 CAPLUS

CN Carbamic acid, [4-(2-amino-4-thiazolyl)phenyl]-, 2-thiazolylmethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 1999:549264 CAPLUS
DOCUMENT NUMBER: 131:184944
TITLE: Preparation of phenyl and aryl-fused thiazole derivatives as antiviral agents for suppression and treatment of herpes family viral infections and sexually-transmitted viral diseases
INVENTOR(S): Flygare, John A.; Jaen, Juan C.; Kearney, Patrick C.; Medina, Julio C.; Sivaraja, Mohanram
PATENT ASSIGNEE(S): Tularik Inc., USA
SOURCE: PCT Int. Appl., 70 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9942455	A1	19990826	WO 1999-US2947	19990210
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9932892	A1	19990906	AU 1999-32892	19990210
PRIORITY APPLN. INFO.:			US 1998-75224P P	19980219
			WO 1999-US2947 W	19990210

OTHER SOURCE(S): MARPAT 131:184944
GI



I



II

AB Ph and aryl-fused thiazole derivs. (I) [where X = S, O, NH, or N-lower alkyl; Y = (un)substituted CH or N; or XY = triat. divalent unit of CH, C-alkyl, and N (3 subunits may not all be N); R1 = H, lower alkyl, or taken together with Y forms a 5- or 6-membered ring; R2, R3, and R4 = independently H, (hetero)alkyl, (hetero)arylalkyl, halogen, CN, NO2, (aryl)alkoxy, (un)substituted sulfamoyl, (un)substituted amino, OH, etc.; R5 = H, lower (aryl)alkyl, aryl, (un)substituted amino; with

provisos] were prepared as antiviral agents useful in the suppression and treatment of sexually-transmitted viral diseases and herpes family viral infections, especially HSV1, HSV2, Epstein Barr virus, and varicella zoster virus. Thus, 2-iodophenacyl bromide was added to thiourea in dioxane and stirred at room temperature for eight hours to yield 2-amino-4-(2-iodophenyl)thiazole (II). Nine compds. of the invention were tested for antiviral activity using an HSV-1 gel primase assay and exhibited IC50 values ranging from 5 μM to 100 μM.

IT **240136-45-2P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph and aryl-fused thiazole derivs. as antiviral agents for herpes family viral infections and sexually-transmitted viral diseases)

RN 240136-45-2 CAPLUS
CN Carbamic acid, [4-(2-amino-4-thiazolyl)-2-nitrophenyl]-, 1-(phenylmethyl)-2-(2-pyridinyl)ethyl ester (9CI) (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

FILE 'CAOLD' ENTERED AT 16:54:30 ON 24 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

L5 0 L2

FILE 'USPATFULL' ENTERED AT 16:54:35 ON 24 APR 2006

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Apr 2006 (20060420/PD)
FILE LAST UPDATED: 20 Apr 2006 (20060420/ED)
HIGHEST GRANTED PATENT NUMBER: US7032245
HIGHEST APPLICATION PUBLICATION NUMBER: US2006085880
CA INDEXING IS CURRENT THROUGH 20 Apr 2006 (20060420/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Apr 2006 (20060420/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

L6 3 L2

L6 ANSWER 1 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2006:41281 USPATFULL
TITLE: Compounds having beta adrenergic receptor agonist and muscarinic receptor antagonist activity
INVENTOR(S): Mammen, Mathai, Redwood Shores, CA, UNITED STATES
Mischki, Trevor, Ottawa, CANADA
Hughes, Adam, Belmont, CA, UNITED STATES
Ji, Yu-Hua, Redwood City, CA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2006035933	A1	20060216	
APPLICATION INFO.:	US 2005-204263	A1	20050815	(11)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2004-601779P	20040816 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: THERAVANCE, INC., 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO, CA, 94080, US
NUMBER OF CLAIMS: 41
EXEMPLARY CLAIM: 1
LINE COUNT: 4900
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB This invention provides compounds of formula I: ##STR1## wherein R.sup.1, R.sup.2, R.sup.4, R.sup.5, R.sup.6, R.sup.7, R.sup.8a, R.sup.8b, W, a, b, c and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The compounds of this invention possess both β.sub.2 adrenergic receptor agonist and muscarinic receptor antagonist activity. Accordingly, such compounds are expected to be useful as therapeutic agents for treating pulmonary disorders, such as chronic obstructive pulmonary disease and asthma.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2005:318933 USPATFULL
TITLE: M3muscarinic acetylcholine receptor antagonists
INVENTOR(S): Laine, Dramane I., King of Prussia, PA, UNITED STATES
Bell, Richard, Stevenage, UNITED KINGDOM
Busch-Petersen, Jakob, King of Prussia, PA, UNITED STATES
Palovich, Michael R., King of Prussia, PA, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005277676	A1	20051215	
APPLICATION INFO.:	US 2003-523478	A1	20030806	(10)
	WO 2003-US24569		20030806	
			20050204	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-60401756	20020806

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SMITHKLINE BEECHAM CORPORATION, CORPORATE INTELLECTUAL PROPERTY-US, UW2220, P. O. BOX 1539, KING OF PRUSSIA, PA, 19406-0939, US
NUMBER OF CLAIMS: 9
EXEMPLARY CLAIM: 1
LINE COUNT: 3908
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB M.sub.3 Muscarinic Acetylcholine Receptor Antagonists and methods of using them are provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 3 USPATFULL on STN
ACCESSION NUMBER: 2002:238064 USPATFULL
TITLE: Handle structure for a snowboard
INVENTOR(S): Carr, Donald W., 339 Scott Ave., Syracuse, NY, United States 13224

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 6450512	B1	20020917	
APPLICATION INFO.:	US 1998-75224		19980511	(9)

DOCUMENT TYPE: Utility
FILE SEGMENT: GRANTED
PRIMARY EXAMINER: Mar, Michael
LEGAL REPRESENTATIVE: Bollman, William H.
NUMBER OF CLAIMS: 12
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 7 Drawing Figure(s); 6 Drawing Page(s)
LINE COUNT: 433
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AB A sportsboard such as a snowboard or wakeboard includes board structure having a handle structure defining a generally smooth surface to be grasped by at least a portion of a hand of the user such that (1) the user may remain in contact with the board structure when the bottom surface of the board structure is out of contact with the medium being ridden and (2) the board structure may be transported by hand more easily by the user. In one embodiment, an opening sufficiently sized to receive the forefingers of a rider's hand is formed in at least one end of the sportsboard. In another embodiment, at least two openings are formed on at least one end of the sportsboard, the two openings being on opposite sides of a lengthwise center axis of the sportsboard. In a third embodiment, at least one end of the sportsboard is rolled-up sufficiently to form a lip which can be grasped by the thumb or forefingers of a rider. In another embodiment, a grip member is formed on an outer edge of at least one end of the sportsboard to allow easy gripping,

particularly when performing aerial tricks. In other embodiments, a separately molded handle structure is mounted to an upper surface of the sportsboard. Methods of modifying convention sportsboards to provide handle structure thereon are also provided.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

FILE 'MEDLINE' ENTERED AT 16:54:49 ON 24 APR 2006

FILE 'BIOSIS' ENTERED AT 16:54:49 ON 24 APR 2006

FILE 'EMBASE' ENTERED AT 16:54:49 ON 24 APR 2006

L7 0 L2

FILE 'MARPAT' ENTERED AT 16:54:55 ON 24 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE CONTENT: 1961-PRESENT VOL 144 ISS 16 (20060421/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US	2006035965	16 FEB 2006
DE	102005008856	09 FEB 2006
EP	1624071	08 FEB 2006
JP	2006050780	16 FEB 2006
WO	2006026533	09 MAR 2006
GB	2416167	18 JAN 2006
FR	2874024	10 FEB 2006
RU	2269538	10 FEB 2006
CA	2512063	14 JAN 2006

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

L8 STR



REP G1=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM

MLEVEL IS CLASS AT 11 13
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS M1 N AT 11
ECOUNT IS E3 C E1 N E1 S AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 13

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L10 42 SEA FILE=MARPAT SSS FUL L8 (MODIFIED ATTRIBUTES)
L11 STR



REP G1=(1-2) C
REP G2=(1-2) C
REP G3=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 13
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E3 C E1 N E1 S AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L12 12 SEA FILE=MARPAT SUB=L10 SSS FUL L11 (MODIFIED ATTRIBUTES)
L13 9 SEA FILE=MARPAT ABB=ON PLU=ON L12/COMPLETE ← Restrict to cites w/ complete iteration

L13 ANSWER 1 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 142:56307 MARPAT
TITLE: Preparation of hydantoin derivatives as inhibitors of tumor necrosis factor-α converting enzyme (tace)
INVENTOR(S): Duan, Jingwu; Xue, Chu-Biao; Sheppeck, James; Jiang, Bin; Chen, Lihua
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004108086	A2	20041216	WO 2004-US17538	20040603
WO 2004108086	A3	20050331		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004254231	A1	20041216	US 2004-858978	20040602
EP 1628974	A2	20060301	EP 2004-776254	20040603
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
PRIORITY APPLN. INFO.:			US 2003-476287P	20030605
			WO 2004-US17538	20040603

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The authors prepared hydantoin derivs. I [R1 = Q, C1-C6 alkylene-Q, (CRaRa1)tNRaSO2NRa(CRaRa1)s-Q, etc.; L = bond, CO, (CR2R3)m, R2 = Q1, C2-C6 alkenylene-Q1, C2-C6 alkynylene-Q1, (CRaRa1)rOC(O)NRa(CRaRa1)s-Q1, etc.; R3 = Q, C1-C6 alkylene-Q, C2-C6 alkenylene-Q, C2-C6 alkynylene-Q, (CRaRa1)rO(CRaRa1)s-Q, etc.; Q = H, CHF2, CH2F, CF3, carbocycle, heterocycle; Q1 = H, carbocycle, heterocycle; Z0 = heterocycle; R11 = W-U-X-Y-Z-Ua-Xa-Ya-Za; W = bond, (CRaRa1)m, C2-C3 alkylene, C2-C3 alkynylene; U = none, O, NRa1, CO, CO2, CONRa1, etc.; X = none, C1-C3 alkylene, C2-C3 alkenylene, C2-C3 alkynylene; Y = none, O, NRa1, S(O)p, CO; Z = C3-C13 carbocycle, heterocycle; Ua = none, O, NRa1, CO, S(O)pNRa1, etc.; Xa = none, C1-C10 alkylene, C2-C10 alkenylene, C2-C10 alkynylene; Ya = none, O, NRa1, S(O)p, CO; Za = C3-C13 carbocycle, heterocycle; Ra = H, C1-C6 alkyl, Ph, PhCH2; Ra1 = H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkylnyl, etc.; R4, R5 = H, C1-C4 alkyl, C2-C4 alkenyl, C2-C4 alkynyl; m = 1-3; p = 0-2; r = 0-4; s = 0-4; t = 1-4] to be used as inhibitors of matrix metalloproteinases (MMP), TNF-α converting enzyme (TACE), and aggrecanase and for treating inflammatory disorders. For example, hydantoin derivative II was prepared starting from 4-HOC6H4CHO and 4-chloromethyl-2-methylquinoline which upon reaction gave aldehyde III. III was reacted with hydroxylamine to give the oxime which added to acrolein to give isoxazolecarbaldehyde IV. IV was then converted to the hydantoin II

upon treatment with KCN/(NH4)2CO3/EtOH/H2O.

L13 ANSWER 2 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 140:181438 MARPAT
TITLE: Preparation of piperidinylmethyl (thiazolyl)phenylcarbamates as M3 muscarinic acetylcholine receptor antagonists
INVENTOR(S): Laine, Dramane I.; Bell, Ricahrd; Busch-Petersen, Jakob; Palovich, Michael
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 116 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004012684	A2	20040212	WO 2003-US24569	20030806
WO 2004012684	A3	20040624		
W: AE, AG, AL, AU, BA, BB, BR, BZ, CA, CN, CO, CR, CU, DM, DZ, EC, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LC, LK, LR, LT, LV, MA, MG, MK, MN, MX, NO, NZ, OM, PH, PL, RO, SC, SG, TN, TT, UA, US, UZ, VN, YU, ZA				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003261392	A1	20040223	AU 2003-261392	20030806
EP 1549278	A2	20050706	EP 2003-767232	20030806
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006505517	T2	20060216	JP 2004-526043	20030806
US 2005277676	A1	20051215	US 2005-523478	20050204
PRIORITY APPLN. INFO.:			US 2002-401756P	20020806
			WO 2003-US24569	20030806

GI



I



II

AB Title compds. I [wherein R1 = halogen, alkyl, CH2F, CHF2; R2 = H, OH, alkyl, aryl, halogen, alkoxy; R3 = H, (cyclo)alkyl, alkenyl, alkenylaryl, (un)substituted alkylaryl, cycloalkylalkyl; R6, R7 = independently H, alkyl; or R6 and R7 together form an (un)substituted (hetero)cyclic ring; n = 1-2; m = 1-2] were prepared For example, reaction of tert-Bu 4-[[[(2-bromophenyl)amino]carbonyloxy]methyl]piperidine-1-carboxylate with bis(pinacolato)diboron, followed by coupling reaction with 2-bromothiazole and deprotection with CF3CO2H, afford II•CF3CO2H. Thus, I and their pharmaceutical compns. are useful as M3 muscarinic acetylcholine receptor antagonists for the treatment of chronic obstructive lung disease, chronic bronchitis, asthma, chronic respiratory obstruction, pulmonary fibrosis, pulmonary emphysema, and allergic rhinitis, irritable bowel syndrome, spasmodic colitis, gastroduodenal ulcers, gastrointestinal convulsions or hyperanakinesia, diverticulitis, pain accompanying spasms of gastrointestinal smooth musculature; urinary-tract disorders accompanying micturition disorders, neurogenic pollakiuria, neurogenic bladder, nocturnal enuresis, psychosomatic bladder, incontinence associated with bladder spasms or chronic cystitis, urinary urgency or pollakiuria, and motion sickness (no data).

L13 ANSWER 3 OF 9 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER:	139:164789 MARPAT
TITLE:	Preparation of phenylpyrazoles as 5-HT2A serotonin receptor modulators
INVENTOR(S):	Teegarden, Bradley; Drouet, Keith; Jayakumar, Honnappa; Thomsen, William; Maffuid, Paul; Elwell, Katie; Foster, Richard; Lawless, Michael; Liu, Qian; Smith, Julian; Feichtinger, Konrad
PATENT ASSIGNEE(S):	Arena Pharmaceuticals, Inc., USA
SOURCE:	PCT Int. Appl., 266 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003062206	A2	20030731	WO 2003-US2059	20030123
WO 2003062206	A3	20040108		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1509505	A2	20050302	EP 2003-705889	20030123

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:
US 2002-386198P 20020123
US 2002-386384P 20020605
US 2002-401467P 20020805
WO 2003-US2059 20030123

GI



I



II

AB Title compds. I [wherein R1 = H, halo, NR5R6, OH, or OR7; R2 = H, (cyclo)alkyl, or alkenyl; R3 = halo, carboxy, CN, or (un)substituted alkoxycarbonyl, (cyclo)alkyl, alkenyl, alkynyl, or (hetero)aryl; R4 = (cyclo)alkyl or alkenyl; R5 and R6 = independently H or (un)substituted (cyclo)alkyl, alkenyl, aryl(methyl); or NR5R6 =

(un)substituted heterocyclyl; R7 = H or alkyl; A = CO, CS, or SO2; B = (NR11)q(CHR12)m(1,2-cyclopropylidene)nQ1 or OQ2; m, n, and q = independently 0-1; R11 and R12 = independently H, (cyclo)alkyl, or alkenyl; Q = (un)substituted Ph; Q2 = (un)substituted (cyclo)alkyl, alkenyl, alkynyl, alkylaryl, or aryl(alkyl); and pharmaceutically acceptable salts thereof] were prepared as modulators of the 5-HT2A serotonin receptor. For example, reaction of triphosgene with 3-(3-aminophenyl)-4-bromo-2-methylpyrazole in the presence of TEA in CH2Cl2, followed by addition of 4-(trifluoromethoxy)benzylamine provided the N-(pyrazolylphenyl)urea II (68%). The latter exhibited IC50 values of 1.2 μM, 0.45 μM, and 0.0171 μM for AP-1, WT 5-HT2A, and AP-3, resp., in a competitive binding assay. A number of the compds. of the invention evidenced inverse agonist activity against AP-1 (data given). Thus, I and pharmaceutical compns. thereof are directed to methods useful in the prophylaxis or treatment of reducing platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia and NOS schizophrenia, and related disorders (no data). The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered sep. or together.

L13 ANSWER 4 OF 9 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 133:89437 MARPAT

TITLE: Preparation of heteroaryl-substituted aromatic amides as factor Xa inhibitors

INVENTOR(S): Beight, Douglas Wade; Craft, Trelia Joyce; Denny, Carl Penman; Franciskovich, Jeffry Bernard; Goodson, Theodore, Jr.; Hall, Steven Edward; Herron, David Kent; Joseph, Sajan Pariyadan; Klimkowski, Valentine Joseph; Masters, John Joseph; Mendel, David; Milot, Guy; Pineiro-Nunez, Marta Maria; Sawyer, Jason Scott; Shuman, Robert Theodore; Smith, Gerald Floyd; Tebbe, Anne Louise; Tinsley, Jennifer Marie; Weir, Leonard Crayton; Wikel, James Howard; Wiley, Michael Robert; Yee, Ying Kwong

PATENT ASSIGNEE(S): Eli Lilly and Co., USA; Kyle, Jeffrey, Alan; et al.

SOURCE: PCT Int. Appl., 403 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039118	A1	20000706	WO 1999-US29946	19991215

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,

VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

CA 2361149	AA	20000706	CA 1999-2361149	19991215
EP 1140903	A1	20011010	EP 1999-964279	19991215
EP 1140903	B1	20040804		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002533454	T2	20021008	JP 2000-591029	19991215
AT 272633	E	20040815	AT 1999-964279	19991215
ES 2226485	T3	20050316	ES 1999-964279	19991215
US 6635657	B1	20031021	US 2001-857751	20010608
US 2004029874	A1	20040212	US 2003-629760	20030729
US 6759414	B2	20040706		
US 2005282862	A1	20051222	US 2003-629817	20030729
PRIORITY APPLN. INFO.:			US 1998-113556P	19981223
			WO 1999-US29946	19991215
			US 2001-857751	20010608

GI



AB The title compds. [I; A3-A6, together with the two carbons to which they are attached, complete a substituted benzene in which A3 = CR3, A4 = CR4, A5 = CR5, and A6 = CR6 (wherein R3 = H, Me, MeO, etc.; one of R4 and R5 = H, alkyl, halo, etc.; the other of R4 and R5 = H; R6 = H, Me, F, etc.); L1 = CONH; Q1 = 2-pyridinyl (un)substituted at the 5-position, 3-pyridinyl (un)substituted at the 6-position, 2-pyrimidinyl (un)substituted at the 5-position, etc.; R2 = L2Q2 (L2 = NHCO, NHCH2, OCH2, etc.; Q2 = (un)substituted piperidinyl, piperazinyl, Ph, etc.)] and their pharmaceutically acceptable salts, useful as inhibitors of factor Xa (no data), were prepared and formulated. E.g., a multi-step synthesis of II.HCl was given. In general, compds. I are effective at 0.01-1000 mg/kg/day.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 5 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 130:81510 MARPAT
TITLE: Preparation of phenylpyrazolecarboxamides as coagulation factor Xa inhibitors
INVENTOR(S): Galemmo, Robert Anthony, Jr.; Dominguez, Celia; Fevig, John Matthew; Han, Qi; Lam, Patrick Yuk-sun; Pinto, Donald Joseph Philip; Pruitt, James Russell; Quan, Mimi Lifen

PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA
SOURCE: PCT Int. Appl., 259 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857937	A2	19981223	WO 1998-US12681	19980618
WO 9857937	A3	19990318		
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9805251	A	19991217	ZA 1998-5251	19980617
CA 2290982	AA	19981223	CA 1998-2290982	19980618
AU 9881503	A1	19990104	AU 1998-81503	19980618
US 5998424	A	19991207	US 1998-99752	19980618
EP 991625	A2	20000412	EP 1998-931355	19980618
EP 991625	B1	20050601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810151	A	20000808	BR 1998-10151	19980618
EE 9900584	A	20000815	EE 1999-584	19980618
SI 20208	C	20001031	SI 1998-20043	19980618
JP 2002507968	T2	20020312	JP 1999-504786	19980618
AT 296805	E	20050615	AT 1998-931355	19980618
ES 2239806	T3	20051001	ES 1998-931355	19980618
US 6403620	B1	20020611	US 1999-393782	19990910
LV 12516	B	20010320	LV 1999-177	19991216
NO 9906316	A	19991217	NO 1999-6316	19991217
LT 4702	B	20000925	LT 1999-146	19991217
US 2003092740	A1	20030515	US 2002-150698	20020516
US 6602895	B2	20030805		
PRIORITY APPLN. INFO.:			US 1997-50219P	19970619
			US 1997-878885	19970619
			US 1998-76691P	19980227
			US 1998-99752	19980618
			WO 1998-US12681	19980618
			US 1999-393782	19990910

GI



II

AB EZ1M [I; E = halo, OH, alkyl, alkoxy, etc.; M = Z2ZAB; A = (un)substituted carbocyclylene, -heterocyclylene; B = H, Y, XY; X = alkylene, CO, O, (un)substituted NH, etc.; Y = amino(alkyl),

substituted carbocyclyl, -heterocyclyl, etc.; Z = bond, (heteroatom- or functional group-interrupted) alkylene, etc.; Z1 = (un)substituted Ph, Z2 = N-containing heteroarylene, etc.] were prepared Thus, MeCOCH2C(:NOMe)CO2Et was cyclocondensed with PhNHNH2 and the product amidated by 4-(H2N)C6H4C6H4(SO2NHCMe3)-2 to give, after deprotection, title compound II. Data for biol. activity of I were given.

L13 ANSWER 6 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 130:66494 MARPAT
TITLE: Preparation of novel guanidine mimics as factor Xa inhibitors
INVENTOR(S): Lam, Patrick Y.; Clark, Charles G.; Dominguez, Celia; Fevig, John Matthew; Han, Qi; Li, Renhua; Pinto, Donald Joseph-Phillip; Pruitt, James Russell; Quan, Mimi Lifen
PATENT ASSIGNEE(S): The Du Pont Merck Pharmaceutical Company, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9857951	A1	19981223	WO 1998-US12680	19980618
W: AU, BR, CA, CN, CZ, EE, HU, IL, JP, KR, LT, LV, MX, NO, NZ, PL, RO, SG, SI, SK, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
ZA 9805247	A	19991217	ZA 1998-5247	19980617
CA 2291442	AA	19981223	CA 1998-2291442	19980618
AU 9879768	A1	19990104	AU 1998-79768	19980618
AU 756755	B2	20030123		
EP 991638	A1	20000412	EP 1998-930361	19980618
EP 991638	B1	20050817		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, SI, LT, LV, FI, RO				
BR 9810137	A	20000808	BR 1998-10137	19980618
EE 9900583	A	20000815	EE 1999-583	19980618
EE 4153	B1	20031015		
JP 2002505686	T2	20020219	JP 1999-504785	19980618
NZ 502370	A	20021025	NZ 1998-502370	19980618
AT 302198	E	20050915	AT 1998-930361	19980618
ES 2244064	T3	20051201	ES 1998-930361	19980618
TW 544453	B	20030801	TW 1998-87109910	19980819
NO 9905965	A	19991203	NO 1999-5965	19991203
NO 318359	B1	20050307		
MX 9911908	A	20000531	MX 1999-11908	19991216
LV 12496	B	20010120	LV 1999-178	19991216
LT 4705	B	20000925	LT 1999-147	19991217
PRIORITY APPLN. INFO.:			US 1997-878884	19970619
			WO 1998-US12680	19980618

GI



AB The title compds. [I; rings D-E represent guanidine mimics; ring D = CH2N:CH, CH2CH2N:CH, a 5-6 membered aromatic system containing 0-2 heteroatoms selected form the group N, O, and S; ring D is substituted with 0-2 R (substituents), provided that when ring D is unsubstituted, it contains at least one heteroatom; ring E contains 0-2 N atom and is substituted by 0-1 R; R = halo, OH, C1-3 alkoxy, etc.; M = (un)substituted pyrazole, imidazole, tetrazole, etc.], inhibitors of factor Xa which are useful in treating and preventing a thromboembolic disorder, were prepared and formulated. Thus, a multi-step synthesis of the title compound II, starting with 7-aminoisoquinoline, was described. A number of compds. I were found to exhibit a Ki of ≤ 15 μM against factor Xa.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 7 OF 9 MARPAT COPYRIGHT 2006 ACS on STN

ACCESSION NUMBER: 129:109090 MARPAT

TITLE: Preparation of nitrogen-containing heteroaromatics as factor Xa inhibitors

INVENTOR(S): Pinto, Donald Joseph Phillip; Pruitt, James Russell; Cacciola, Joseph; Fevig, John Matthew; Han, Qi; Orwat, Michael James; Quan, Mimi Lifen; Rossi, Karen Anita

PATENT ASSIGNEE(S): The Dupont Merck Pharmaceutical Co., USA

SOURCE: PCT Int. Appl., 438 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9828269	A1	19980702	WO 1997-US22895	19971215
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2275796	AA	19980702	CA 1997-2275796	19971215
AU 9856020	A1	19980717	AU 1998-56020	19971215
AU 730224	B2	20010301		
EP 946508	A1	19991006	EP 1997-952409	19971215

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI

EE 9900316	A	20000215	EE 1999-316	19971215
SI 20017	C	20000229	SI 1997-20082	19971215
CN 1246847	A	20000308	CN 1997-181852	19971215
BR 9714073	A	20000509	BR 1997-14073	19971215
JP 2001509145	T2	20010710	JP 1998-528845	19971215
ZA 9711586	A	19990701	ZA 1997-11586	19971223
TW 492971	B	20020701	TW 1997-86119637	19980203
NO 9902633	A	19990820	NO 1999-2633	19990601
NO 313190	B1	20020826		
MX 9905878	A	20000131	MX 1999-5878	19990622
LT 4673	B	20000725	LT 1999-76	19990622
LV 12430	B	20000720	LV 1999-99	19990730
PRIORITY APPLN. INFO.:			US 1996-769859	19961223
			US 1997-879944	19970620
			WO 1997-US22895	19971215

GI



I II

AB The title compds. [I; ring M contains, in addition to J, 0-3 N atoms; J = N, NH; D = CN, C(:NR8)NR7R9, C(O)NR7R8, etc.; E = (un)substituted Ph, pyridyl, pyrimidinyl, etc.; DEG = R-substituted pyridyl; R = H, halo, CF3, etc.; G = absent, NHCH2, OCH2, etc.; Z = C1-4 alkylene, (CH2)rO(CH2)r, etc.; R1a, R1b = absent, NMe, OMe, etc.; A = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S; B = (un)substituted C3-10 carbocyclic residue, 5-10 membered heterocyclic containing from 1-4 heteroatoms selected from N, O, and S, etc.; R7 = H, OH, C1-6 alkyl, etc.; R8, R9 = H, C1-6 alkyl, (CH2)nPh; n = 0-3; r = 0-3; s = 0-2], useful as inhibitors of factor Xa, were prepared and formulated. Thus, treatment of 4-[o-(tert-BuSO2)phenyl]aniline with Me3Al/hexane in CH2Cl2 followed by the addition of Me 1-(3-cyanophenyl)imidazol-2-ylcarboxylate (preparation described), and the Pinner reaction of the resulting intermediate afforded the title compound II. A number of compds. I were found to exhibit a Ki of ≤ 10 μM against factor Xa. Some compds. I were evaluated and found to exhibit Ki of < 10 μM against thrombin.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L13 ANSWER 8 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 127:247921 MARPAT
TITLE: Preparation of 3,5-bis(amidinophenyl)pentanoates and analogs as factor Xa inhibitors

Searcher : Shears 571-272-2528

INVENTOR(S): Maduskuie, Thomas Peter, Jr.; Cacciola, Joseph; Fevig, John Matthew; Quan, Mimi Lifen; Stouten, Petrus Fredericus Wilhelmus
PATENT ASSIGNEE(S): Du Pont Merck Pharmaceutical Co., USA
SOURCE: PCT Int. Appl., 141 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9730971	A1	19970828	WO 1997-US2919	19970218
W: AM, AU, AZ, BR, BY, CA, CN, CZ, EE, HU, IL, JP, KG, KR, KZ, LT, LV, MD, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, UA, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2244851	AA	19970828	CA 1997-2244851	19970218
AU 9720561	A1	19970910	AU 1997-20561	19970218
EP 892780	A1	19990127	EP 1997-908723	19970218
EP 892780	B1	20021120		
R: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
AT 228111	E	20021215	AT 1997-908723	19970218
PT 892780	T	20030228	PT 1997-908723	19970218
ES 2186874	T3	20030516	ES 1997-908723	19970218

PRIORITY APPLN. INFO.: US 1996-12104P 19960222
US 1996-644085 19960509
US 1997-36823P 19970203
WO 1997-US2919 19970218

GI



I

AB RbRa(CH2)pX(ED)ZAB [A = (0-2 R4-substituted) CH2PH, carbocyclic residue, heterocyclic system; B = H, NR1R4, COR6, alkyl, etc.; D = cyano, C(:NR7)NR8R9, CONR8R9, etc.; E = phenylene, pyridinediyl, pyrimidinediyl, piperidinediyl; Ra = bond or CH:CH; Rb = H COR, OG1, NG1G2, etc.; G1 = H, alkyl, heterocyclyl, etc.; G2 = H or alkyl; R = H, OH, alkyl, alkoxy, etc.; R1 = H, alkyl, alkoxy, etc.; R4 = H, halo, OH, alkyl, etc.; R6 = H, OH, alkyl, alkoxy, etc.; R8,R9 = H or (phenyl)alkyl; X = CHCH(R1), CHN(R1), CH-O, CR1, N, and NCH(R1) (sic);

Z = (CH2)n, CO, CO(CH2)n, CONR1; XZ = CR1(CH2)qSOm(CH2)q, N(CH2)qSOmNR6(CH2)q, etc.; m,q = 0-2; p,n = 1-4] were prepared as factor Xa inhibitors (no data). Thus, 4-(NC)C6H4CHO underwent aldol condensation with 3-(NC)C6H4COMe and the product condensed with MeO2CCH:P(Ph)3 to give, in 2 addnl. steps, title compound I.

L13 ANSWER 9 OF 9 MARPAT COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 127:51002 MARPAT
TITLE: Inhibitors of protein isoprenyl transferases
INVENTOR(S): Sebti, Said M.; Hamilton, Andrew D.; Rosenberg, Saul H.; Augeri, David J.; Barr, Kenneth J.; Donner, Bernard G.; Fakhhoury, Stephen A.; Janowick, David A.; Kalvin, Douglas M.; Larsen, John J.; Liu, Gang; O'Connor, Stephen J.; Shen, Wang; Swenson, Rolf E.; Sorenson, Bryan K.; Sullivan, Gerard M.; Szczepankiewicz, Bruce; Tasker, Andrew S.; Wasicak, James T.; Winn, Martin
PATENT ASSIGNEE(S): University of Pittsburgh, USA
SOURCE: PCT Int. Appl., 260 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9717070	A1	19970515	WO 1996-US17092	19961105
W: AU, BR, CA, CN, CZ, HU, IL, JP, KR, MX, NZ				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
CA 2235986	AA	19970515	CA 1996-2235986	19961105
AU 9675975	A1	19970529	AU 1996-75975	19961105
ZA 9609273	A	19980505	ZA 1996-9273	19961105
EP 873123	A1	19981028	EP 1996-938647	19961105
EP 873123	B1	20030409		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2000500745	T2	20000125	JP 1997-518208	19961105
AT 236632	E	20030415	AT 1996-938647	19961105
PT 873123	T	20030829	PT 1996-938647	19961105
ES 2196186	T3	20031216	ES 1996-938647	19961105
PRIORITY APPLN. INFO.:			US 1995-7247P	19951106
			WO 1996-US17092	19961105

AB Protein isoprenyl transferase inhibitors R3XC6H2R1R2R4 [R1 = H, alkyl, halo, aryl, heterocyclyl, etc.; R2 = (un)substituted Ph, CONHCHR5CO2R6 (R5 = alkyl, cycloalkyl, etc., R6 = H or protecting group); CONH-heterocyclyl, etc.; R3 = (un)substituted pyridyl or imidazolyl; R4 = H, alkyl, halo, aryl, etc.; X is absent or X1NR4X2, X1OX2 (X1 = absent, alkylene, or alkenylene; X2 = absent, CH2, CH2CH2, CHMe, etc.)] were prepared Thus, [4-(3-pyridyloxymethylene)-2-phenoxybenzoyl]methionine (I) was prepared by coupling of 4-(3-pyridyloxymethylene)-2-phenoxybenzoic acid (synthesis described) with methionine Me ester hydrochloride, followed by saponification Compound I showed 92% inhibition of protein farnesyl transferase at 1 μM.

FILE 'REGISTRY' ENTERED AT 16:59:28 ON 24 APR 2006
L14 315199 S ?CARBAMIC ACID?/CNS

-key terms Compd.

```
L15      936652 S ?PIPERIDIN?/CNS
L16       17659 S L14(L)L15
L17     1147742 S ?THIAZOL?/CNS
L18         567 S L16(L)L17
L19     4274872 S ?CHLORO?/CNS
L20          61 S L18(L)L19

     FILE 'CAPLUS' ENTERED AT 17:01:05 ON 24 APR 2006
L21          21 S L20
L22         199 S (4(W)(CL OR CHLORO?))(S)CARBAMIC
L23          11 S L22(S)PIPERIDIN?
L24          32 S (L21 OR L23) NOT L4
L25           8 S L24 NOT (PY=>2002 OR PD=>20020806)
```

L25 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 18 Oct 2004
ACCESSION NUMBER: 2004:856523 CAPLUS
DOCUMENT NUMBER: 142:56179
TITLE: Process for preparation of intermediates of triscarbamic acid esters
INVENTOR(S): Kim, Gun Sik; Kim, Young Jung; Lee, Dong Il; Kim, Hyun Mo
PATENT ASSIGNEE(S): Korea Fine Chemical Co., Ltd, S. Korea
SOURCE: Repub. Korea, No pp. given
CODEN: KRXXFC
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 235338	B1	19991215	KR 1997-57468	19971031
PRIORITY APPLN. INFO.:			KR 1997-57468	19971031

AB Provided is a method for preparing an intermediate of tris-carbamic acid ester, which is an inhibitor of cholesterol, by using environmentally friendly water solution and base. In a method for preparing an intermediate of tris-**carbamic** acid ester, **4**-(**chlorocarbonyloxy**)-1-**piperidinecarboxylic** acid 4-phenoxyphenyl ester of the formula (I) reacts with aminohexanol to prepare high purity 4-((((6-hydroxyhexyl)amino)carbonyl)oxy)-**piperidinecarboxylic** acid 4-phenoxyphenyl ester of the formula (II) in high yield by using environmentally friendly water solution and bases instead of organic solvents and organic bases which cause environmental pollution. The water solution is preferably a cosolvent of water and an organic solvent, and selected from the group consisting of methylene chloride, ethylene chloride, chloroform, benzene, toluene, xylene, acetonitrile, THF and a mixture thereof. The base is selected form NaOH, KOH, NaHCO3, Na2CO3, KHCO3, Ca(OH)2, Mg(OH)2 and a mixture thereof. The reaction is preferably carried out between 0° to 50°.

L25 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 24 May 2001
ACCESSION NUMBER: 2001:372159 CAPLUS
DOCUMENT NUMBER: 134:366868
TITLE: Preparation of benzothiazolines as neuropeptide Y receptor antagonists

INVENTOR(S): Sato, Yoshiya; Itani, Hiromichi; Tabuchi, Seiichiro; Sakata, Yoshihiko; Ohashi, Hiroko
PATENT ASSIGNEE(S): Fujisawa Pharmaceutical Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 88 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2001139574	A2	20010522	JP 2000-296175	20000928
PRIORITY APPLN. INFO.:			AU 1999-3093 A	19990928

OTHER SOURCE(S): MARPAT 134:366868
GI



I

AB The title compds. I [R1 = H, halo; W = S, O; A = (CH2)n, etc.; n = 1 - 6; Z = (un)substituted N-containing heterocyclic ring] are prepared 1-[(5-Chloro-2-oxobenzothiazolin-3-yl)acetyl]piperidine-4-carboxylic acid 4-benzoylanilide showed IC100 of 10-7 M in a neuropeptide Y5 receptor binding assay.

IT **340180-02-1P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of benzothiazolines as neuropeptide Y receptor antagonists)

IT **340179-82-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of benzothiazolines as neuropeptide Y receptor antagonists)

L25 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 01-Jun 1998
ACCESSION NUMBER: 1998:324806 CAPLUS
DOCUMENT NUMBER: 129:24496
TITLE: Herbicidal 3-(substituted benzoxazol-7-yl) and 3-(substituted benzothiazol-7-yl)-1-substituted-6-trifluoromethyl-2 4-(1H,3H)pyrimidinediones
INVENTOR(S): Crawford, Scott D.; Maravetz, Lester L.; Theodoridis, George
PATENT ASSIGNEE(S): FMC Corp., USA
SOURCE: U.S., 38 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5753595	A	19980519	US 1996-743973	19960731
PRIORITY APPLN. INFO.:			US 1996-743973	19960731

OTHER SOURCE(S): MARPAT 129:24496
GI



I

AB Herbicidal 3-(substituted benzoxazol-7-yl) and 3-(substituted benzothiazol-7-yl)-1 -substituted-6-trifluoromethyl-2,4-(1H,3H)pyrimidinediones I (R = a variety of substituents, including halo, alkyl, alkenyl, alkynyl, Ph, phenylalkyl, alkylphenylalkyl, haloalkyl, hydroxy, alkoxy, hydroxyalkyl, halophenyl, halophenylalkyl, alkoxyphenyl, sulfhydryl, alkylthio, piperidinyl, alkylamino, alkoxyalkyl, phenoxy, amino, alkylsulfonylamino, phenylsulfonylamino, and carboxy; R1 = alkyl or amino; R2 = H or halo; X = O or S; Y = H, halo, alkoxy, cyano, or nitro; Z = halo; where halo is bromine, chlorine, fluorine, or iodine, and each alkyl, alkoxy, alkenyl, or alkynyl moiety has one to six carbon atoms), compns. containing them, and methods of using them to control undesired plant growth are disclosed, as are novel intermediates used in the preparation Thus, Et N-(2-tert-butyl-4-chlorobenzoxazol-7-yl)carbamate, prepared in 3 steps from 2,5-dichloroaniline was cyclized with 3-amino-4,4,4-trifluorocrotonate followed by methylation to give N-(2-tert-butyl-4-chlorobenzoxazol-7-yl)-1-methyl-6-(trifluoromethyl)-2,4-(1H,3H)pyrimidinedione (II). In preemergence and postemergence application II completely controlled Johnson grass at 0.3 kg/ha.

IT **188787-80-6P 188787-88-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of herbicidal 3-(substituted benzoxazol-7-yl)- and 3-(substituted benzothiazol-7-yl)-1-substituted-6-trifluoromethyl-2 4-(1H,3H)pyrimidinediones)

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L25 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 19 Jan 1998
ACCESSION NUMBER: 1998:31312 CAPLUS
DOCUMENT NUMBER: 128:102394
TITLE: Preparation of pyrrolo[1,2-a]pyrazine-1,4-dione serine protease inhibitors
INVENTOR(S): Berryman, Kent Alan; Doherty, Annette Marian; Edmunds, Jeremy John; Siddiqui, M. Arshad

PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: PCT Int. Appl., 71 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9748706	A1	19971224	WO 1997-US9832	19970610
W: AL, AU, BA, BB, BG, BR, CA, CN, CZ, EE, GE, GH, HU, IL, IS, JP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9732325	A1	19980107	AU 1997-32325	19970610
US 6124291	A	20000926	US 1998-171863	19981027
PRIORITY APPLN. INFO.:			US 1996-19989P P	19960618
			WO 1997-US9832 W	19970610

OTHER SOURCE(S): MARPAT 128:102394
GI



I



II

AB This invention relates to pyrrolo[1,2-a]pyrazine-1,4-diones I (B = CO,

CH2; R2, R4, R5, R6 = independently H, alkyl, substituted alkyl; A = basic group; Q = H, keto heterocycle group; p = 0-2). The compds. are inhibitors of serine proteases, typically thrombin, Factor Xa, and Factor VIIa, and are useful for treating and preventing thrombotic disorders. Thus, title derivative II was prepared in 14 steps from Z-Asp-OCMe3 (Z = PhCH2O2C), Ph(CH2)3-Gly-OCH2Ph, Boc-Arg(Mtr)-OH (Boc = Me3CO2C; Mtr = 4-methoxy-2,3,6-trimethylphenylsulfonyl), and thiazole.II inhibited thrombin with Ki = 3 nM, factor Xa at 30 nM, and trypsin <1 nM.

IT **201165-65-3P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrrolopyrazinedione derivs. as antithrombotics and serine protease inhibitors)

L25 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 05 May 1997
ACCESSION NUMBER: 1997:286377 CAPLUS
DOCUMENT NUMBER: 126:264105
TITLE: Herbicidal 3-(substituted benzoxazol-7-yl) and 3-(substituted benzothiazol-7-yl)-1-substituted-6-trifluoromethyl-2,4-(1H,3H)pyrimidinediones
INVENTOR(S): Crawford, Scott D.; Maravetz, Lester L.; Theodoridis, George
PATENT ASSIGNEE(S): FMC Corp., USA
SOURCE: PCT Int. Appl., 94 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9708170	A1	19970306	WO 1996-US13995	19960830
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN				
AU 9669618	A1	19970319	AU 1996-69618	19960830
ZA 9610644	A	19970624	ZA 1996-10644	19961218
PRIORITY APPLN. INFO.:			US 1995-3080P	P 19950831
			WO 1996-US13995	W 19960830

OTHER SOURCE(S): MARPAT 126:264105
GI



I



II



III

AB Herbicidal title compds., compns. containing them, and methods of using them to control undesired plant growth are disclosed, as are novel intermediates used in their preparation The herbicidal compds. are defined as I [R = halo, alk(en/yn)yl, aryl, arylalkyl, alkylarylalkyl, haloalkyl, OH, alkoxy, hydroxyalkyl, haloaryl, haloarylalkyl, alkoxyaryl, SH, alkylthio, piperidinyl, alkylamino, alkoxyalkyl, PhO, amino, alkylsulfonylamino, arylsulfonylamino, CO2H, etc.; R1 = alkyl or amino; R2 = H or halo; X = O or S; Y = H, halo, alkoxy, cyano, or NO2; and Z = halo; where halo = Br, Cl, F, or iodine, and each alkyl moiety has 1-6 C atoms]. A list of 124 possible specific compds. is given, with phys. and biol. data for over 60 compds. For instance, 3-chloro-4-fluoroaniline reacted with trimethylacetic anhydride to give the corresponding amide, which was lithiated with BuLi and treated with CO2 to give 2-(tert-butyl)-6-fluorobenzoxazole-7-carboxylic acid. This acid was treated with ClCO2Et and then NaN3 to give the acyl azide, which was thermolyzed in refluxing EtOH to give the benzoxazole carbamate derivative II [Y = H]. This was chlorinated by N,N-dichlorourethane in concentrated HCl-AcOH to give II [Y = Cl], which underwent cyclocondensation with CF3(H2N)C:CHCO2Et and then N-methylation with MeI and K2CO3 to give title compound III. At 0.3 kg/ha post- or preemergence, III gave nonselective 100% control of all 10 test species, including 3 crops.

IT **188787-80-6P 188787-88-4P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of herbicidal benzoxazolyl- and benzothiazolyl-substituted (trifluoromethyl)pyrimidinediones)

L25 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 20 Dec 1996
ACCESSION NUMBER: 1996:746209 CAPLUS
DOCUMENT NUMBER: 126:19324
TITLE: Preparation of arylsulfonylamino acid amide trypsin and thrombin inhibitors.

INVENTOR(S): Hoyle, William; Howarth, Graham Arton; Brundish, Derek Edward; Kane, Peter Daniel; Walker, Clive Victor; Hayler, Judy; Fullerton, Joseph David; Smith, Garric Paul; Wathey, William Bernard; et al.
PATENT ASSIGNEE(S): Ciba-Geigy A.-G., Switz.
SOURCE: PCT Int. Appl., 202 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629327	A1	19960926	WO 1996-GB520	19960308
W: AL, AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG, KP, KR, KZ, LK, LR, LS, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, TJ, TM, TT, UA, US, UZ, VN				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9648872	A1	19961008	AU 1996-48872	19960308
EP 815103	A1	19980107	EP 1996-904963	19960308
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
JP 11502219	T2	19990223	JP 1996-528155	19960308
ZA 9602112	A	19960918	ZA 1996-2112	19960315
PRIORITY APPLN. INFO.:			GB 1995-5538 A	19950318
			WO 1996-GB520 W	19960308

OTHER SOURCE(S): MARPAT 126:19324
GI

Q1= 

Q2= 

AB ArSO2AQ [Ar = (substituted) aryl, heterocyclyl; A = amino acid residue; Q = Q1, Q2; X = H, alkyl; Y = SO3H, PO(OR14)2, OH, SH, NR15R16, halo, (substituted) (CqH2q)Q3, etc.; Q3 = H, COR14, CO2R14, CONR15R16, SO3H, OR14, OCOR14, PO(OR14)2, NR15R16, SR14, halo; R14, R15, R16 = H, alkyl, cycloalkyl, aralkyl; R15R16N = 5-6 membered azacycloalkyl, oxazacycloalkyl; XY = O; Z = bond, O, N optionally substituted by X or Y; m, n = 2-4; m + n = 4-6, j, k = 0-2; j + k = 2-3; when A = Arg, then X, Y ≠ alkyl; when Q = COR14, then q = 1-8], were prepared Thus, (S)-arginine and 3-(1-methyl-1-phenylethyl)benzenesulfonyl chloride were stirred with Na2CO3 in H2O/dioxane to give 5-guanidino-2(S)-[3-(1-methyl-1-phenylethyl)benzenesulfonylamino]pentanoic acid. The latter was converted to the acid chloride hydrochloride, which was condensed with pyrrolidin-2(R)-ylmethanol in DMF containing Et3N to give

N-[4-guanidino-1(S)-2(R)-hydroxymethylpyrrolidine-1-carbonylbutyl]-3-(1-methyl-1-phenylethyl)benzenesulfonamide. Tested title compds. inhibited human α-thrombin with Ki = 0.007-0.094 μM.

IT **184043-61-6P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of arylsulfonylamino acid amide trypsin and thrombin inhibitors)

L25 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 03 Apr 1989
ACCESSION NUMBER: 1989:114828 CAPLUS
DOCUMENT NUMBER: 110:114828
TITLE: Benzothiazolinone derivatives, their production and antiallergic and antiinflammatory compositions
INVENTOR(S): Umio, Suminori; Kozasa, Shizuo; Yabuuchi, Takahiro
PATENT ASSIGNEE(S): Hoei Pharmaceutical Co., Ltd., Japan; Research Institute for Production Development
SOURCE: Eur. Pat. Appl., 17 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 288973	A2	19881102	EP 1988-106665		19880426
EP 288973	A3	19890816			
EP 288973	B1	19830113			
R: BE, CH, DE, ES, FR, GB, IT, LI, NL, SE					
JP 01301680	A2	19891205	JP 1988-96641		19880419
US 4879301	A	19891107	US 1988-186439		19880426
PRIORITY APPLN. INFO.:			JP 1987-106961	A	19870428
			JP 1988-21754	A	19880201

OTHER SOURCE(S): CASREACT 110:114828; MARPAT 110:114828
GI



AB Title compds. I (A = alkylene; X = halo; R = R1O, R2R3N, YCO2H; R1 = alkyl; R2, R3 = H, alkyl; Y = alkylene, alkenylene) are prepared by reaction of the corresponding alcs. (II) and ZCO2R1 (Z = halo), R4NCO (R4 = alkyl), or a reactive derivative of (HO2C)2Y and reaction of II with Cl2CO or ClCO2CCl3, followed by condensation with R2R3NH. Treatment of II (X = 5-Cl; A = CH2; OH at the 4 position) with ClCO2Et at 80° for 8 h gave I (X = 5-Cl; A = CH2; EtOCO2 at the 4 position) (III), which, at 16 mg/kg orally, showed 50.7% antagonism of passive cutaneous anaphylaxis of rats. Tablets were prepared containing III 5000, lactose 4200, hydroxypropyl cellulose 1700, and Mg stearate 100

parts by weight
IT **119400-41-8P 119400-42-9P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as allergy and inflammation inhibitor)

L25 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
ED Entered STN: 28 Dec 1985
ACCESSION NUMBER: 1985:615287 CAPLUS
DOCUMENT NUMBER: 103:215287
TITLE: Five membered heterocyclic ring containing N-(bicyclic heterocyclyl)-4-piperidinamines
INVENTOR(S): Janssens, Frans Eduard; Torremans, Joseph Leo Ghislanus; Hens, Jozef Francis; Van Offenwert, Theophilus Theresia
PATENT ASSIGNEE(S): Janssen Pharmaceutica N. V., Belg.
SOURCE: Eur. Pat. Appl., 76 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
EP 145037	A2	19850619	EP 1984-201326		19840914
EP 145037	A3	19850710			
EP 145037	B1	19890118			
R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE					
US 4634704	A	19870106	US 1984-625343		19840627
CA 1247614	A1	19881227	CA 1984-462540		19840906
AT 40130	E	19890215	AT 1984-201326		19840914
IL 73118	A1	19880331	IL 1984-73118		19840930
RO 90457	B3	19861210	RO 1984-115894		19841004
DK 8404784	A	19850407	DK 1984-4784		19841005
DK 163239	B	19920210			
DK 163239	C	19920629			
FI 8403934	A	19850407	FI 1984-3934		19841005
FI 81797	B	19900831			
FI 81797	C	19901210			
NO 8404009	A	19850409	NO 1984-4009		19841005
NO 160441	B	19890109			
NO 160441	C	19890419			
AU 8433872	A1	19850418	AU 1984-33872		19841005
AU 565884	B2	19871001			
ES 536590	A1	19851116	ES 1984-536590		19841005
JP 61010577	A2	19860118	JP 1984-208394		19841005
JP 07098818	B4	19951025			
ZA 8407847	A	19860528	ZA 1984-7847		19841005
HU 38629	A2	19860630	HU 1984-3771		19841005
HU 207514	B	19930428			
SU 1440346	A3	19881123	SU 1984-3796140		19841005
PL 146228	B1	19890131	PL 1984-249916		19841005
PRIORITY APPLN. INFO.:			US 1983-539597	A	19831006
			US 1984-625343	A	19840627
			EP 1984-201326	A	19840914

OTHER SOURCE(S): CASREACT 103:215287

GI For diagram(s), see printed CA Issue.

AB The title compds. [I; R = H, alkyl; R1 = H, alkyl, thienyl, halothienyl, pyrazinyl, thiazolyl, alkylthiazolyl, imidazolyl, alkylimidazolyl, (un)substituted Ph, alkyl substituted by 1 or 2 of these aromatic groups; R2 = H, alkyl, cycloalkyl, alkanoyl, alkoxycarbonyl, (un)substituted Ph; R3 = R4(CH2)nZZ1, R4(CH2)nZ2C(X1)ZZ1, Q; R4 = 5-membered heterocyclyl containing ≥1 N atoms, optionally fused to a C6H6 ring; X = (un)substituted CH:CHCH:CH, N:CHCH:CH, CH:NCH:CH, CH:CHN:CH, CH:CHCH:N; X1 = O, S, O2NCH, R5N; R5 = H, alkyl, cyano, NO2, acyl; Z = O, S, R6 N, bond; R6 = H, alkyl, amino, acyl; Z1 = alkylene; Z2 = O, S, R7N, bond; R7 = H, alkyl; n = 0-6; m = 0-2] were prepared Thus, N-(2-nitrophenyl)-2-furanmethanamine was hydrogenated and the diamine condensed with Et 4-isothiocyanato-1-piperidinecarboxylate to give thiourea derivative II. This was cyclized to a benzimidazole derivative by heating with HgO and S in EtOH, decarboxylated by heating in aqueous HBr, and N-alkylated with 4-(chloromethyl)-5-methyl-1H-imidazole-HCl to give benzimidazolamine III. The antihistaminic properties of I were demonstrated in rats, where I inhibited the lethality of compound 48/80 with ED50 0.005-1.25 mg/kg s.c. or orally, and inhibit gastric lesions in rats caused by the same agent with ED50 0.04-1.25 mg/kg s.c.

IT **99138-72-4P**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation and antihistaminic activity of)

FILE 'MEDLINE' ENTERED AT 17:03:31 ON 24 APR 2006

FILE 'BIOSIS' ENTERED AT 17:03:31 ON 24 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 17:03:31 ON 24 APR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 17:03:31 ON 24 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CONFSCI' ENTERED AT 17:03:31 ON 24 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'SCISEARCH' ENTERED AT 17:03:31 ON 24 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'JICST-EPLUS' ENTERED AT 17:03:31 ON 24 APR 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'JAPIO' ENTERED AT 17:03:31 ON 24 APR 2006
COPYRIGHT (C) 2006 Japanese Patent Office (JPO)- JAPIO

L26 5 S L20
L27 6 S L23
L28 11 S L26 OR L27
L29 11 DUP REM L28 (0 DUPLICATES REMOVED)

L29 ANSWER 1 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2005-591611 [60] WPIDS
CROSS REFERENCE: 2004-805062 [79]; 2004-813067 [80]; 2004-832550 [82]; 2004-833676 [82]; 2005-346574 [35]

DOC. NO. CPI: C2005-178281
TITLE: New imidazole derivatives are glutaminyl cyclase inhibitors useful to treat neuronal disorders e.g. Alzheimer's disease, Down syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions and schizophrenia.
DERWENT CLASS: B02 B03
INVENTOR(S): BUCHHOLZ, M; DEMUTH, H; HEISER, U; NIESTROJ, A J; SCHILLING, S
PATENT ASSIGNEE(S): (PROB-N) PROBIODRUG AG
COUNTRY COUNT: 108
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2005075436	A2	20050818	(200560)*	EN	122

RW: AT BE BG BW CH CY CZ DE DK EA EE ES FI FR GB GH GM GR HU IE IS IT KE LS LT LU MC MW MZ NA NL OA PL PT RO SD SE SI SK SL SZ TR TZ UG ZM ZW

W: AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

US 2005215573 A1 20050929 (200564)

APPLICATION DETAILS:

PATENT NO	KIND		APPLICATION	DATE
WO 2005075436	A2		WO 2005-EP1153	20050204
US 2005215573	A1	Provisional	US 2004-542133P	20040205
		CIP of	US 2004-838993	20040505
		Provisional	US 2004-634364P	20041208
			US 2005-51760	20050204

PRIORITY APPLN. INFO: US 2004-634364P 20041208; US 2004-542133P 20040205; US 2004-838993 20040505; US 2005-51760 20050204

AN 2005-591611 [60] WPIDS

CR 2004-805062 [79]; 2004-813067 [80]; 2004-832550 [82]; 2004-833676 [82]; 2005-346574 [35]

AB WO2005075436 A UPAB: 20051006

NOVELTY - Imidazole derivatives (I) and their salts, stereoisomers and polymorphs are new.

DETAILED DESCRIPTION - Imidazole derivatives of formula (I) and their salts, stereoisomers and polymorphs are new.

A = alkyl, alkenyl, alkynyl, substituted phenyl of formulae (a)-(c) or cycloalkyl derivative of formulae (d) or (e);

R6-R10 = H, alkyl, alkenyl, alkynyl, cycloalkyl, carbocycle, (hetero)aryl or heterocycle;

n, n1, m = 1-5;

o = 0-4;

B1 = -NH-C(=X)-NH-D, -C(=X)-NH-D, -C(=X)-S-D, -NH-C(=Y)-C(R17)(R18)-D or heterocyclic derivative of formulae (f)-(g);

D, E = alkyl, alkenyl, alkynyl, cycloalkyl, carbocycle,

alkylaryl, (hetero)aryl, alkylheteroaryl, acyl or heterocycle;
Z = CH or N;
X = CR20R21, O, S or NR19, provided that for formula (f) and (g), Z is CH, X is O or S;
R19 = H, alkyl, cycloalkyl, (hetero)aryl, -oxyalkyl, -oxyaryl, carbonyl, amido, OH, NO2, NH2 or CN;
R20, R21 = H, alkyl, cycloalkyl, heterocycle, (hetero)aryl, oxyalkyl, oxyaryl, carbonyl, amido, NO2, NH2, CN or CF3;
X1-X3 = O or S, provided that X2 and X3 are not both O;
Y = O or S, provided that Y may not be O, when the carbocycle formed by R17 and R18 has 3 members in the ring;
R11-R14 = H, alkyl, alkenyl, alkynyl, cycloalkyl, carbocycle, (hetero)aryl, heterocycle, halo, alkoxy, thioalkyl, carboxyl, carboxylic acid ester, carbonyl, carbamide, (thio)carbamide or thiocarbonyl, NH2 or NO2;
R15, R16 = H, alkyl or alkenyl;
R17, R18 = H, alkyl, alkenyl, alkynyl, carbocycle, (hetero)aryl, heteroalkyl or carbocycle with 0-6 ring atoms; and
n = 0-1.

Provided that the compounds (1)-(4) are excluded, where in (4), X, R is (CH2, 4-F), (CH2, 3-Cl), (CH2, 4-CH3) or (C2H4, H). An INDEPENDENT CLAIM is also included for a composition (A) comprising (I) optionally in combination with a carrier and/or excipient.

ACTIVITY - Neuroprotective; Nootropic; Antiparkinsonian; Anticonvulsant; Neuroleptic; Hypnotic; Endocrine-Gen.; Hypotensive; Antipyretic; Anabolic; Eating-Disorders-Gen.; Tranquilizer; Antidepressant; Antiaddictive; Antialcoholic; Antiinfertility.

MECHANISM OF ACTION - Glutaminyl cyclase inhibitor. The ability of (I) to inhibit glutaminyl cyclase was assessed using biological assay. The results showed that the inhibition constant value of N-(3-(1H-imidazol-1-yl)propyl)-1-(3,4-dimethoxyphenyl)cyclopropanecarbothioamide was 0.09 microM.

USE - (I) are useful in the manufacture of a medicament for the treatment of neuronal disorders, especially Alzheimer's disease, Down syndrome, Parkinson disease, Chorea Huntington, pathogenic psychotic conditions, schizophrenia, impaired food intake, sleep-wakefulness, impaired homeostatic regulation of energy metabolism, impaired autonomic function, impaired hormonal balance, impaired regulation, body fluids, hypertension, fever, sleep dysregulation, anorexia, anxiety related disorders including depression, seizures including epilepsy, drug withdrawal and alcoholism, neurodegenerative disorders including cognitive dysfunction and dementia (claimed). (I) are also useful to stimulate the proliferation of myeloid progenitor cells; or to suppress male fertility.

ADVANTAGE - (I) are more potent, selective and are more compatible or effective in combination with other drugs. (I) has fewer side effects, better formulation and stability properties, better pharmacokinetic properties, and can be more readily synthesized than other known compounds. (I) are more bioavailable and are able to cross blood brain barrier and are more effective in the brain of mammals.
Dwg.0/0

L29 ANSWER 2 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-607827 [57] WPIDS
DOC. NO. CPI: C2003-165555
TITLE: New trisubstituted triazine library, useful as universal small molecule chips for functional proteomics and sensors.
DERWENT CLASS: B03 B04 D16

INVENTOR(S): CHANG, Y; KHERSONSKY, S M; MOON, H
PATENT ASSIGNEE(S): (CHAN-I) CHANG Y; (KHER-I) KHERSONSKY S M; (MOON-I) MOON H; (UYNY) UNIV NEW YORK STATE
COUNTRY COUNT: 101
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003050237	A2	20030619	(200357)*	EN	17
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
US 2003166002	A1	20030904	(200359)		
AU 2002340125	A1	20030623	(200420)		
AU 2002340125	A8	20051020	(200615)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003050237	A2	WO 2002-US32096	20021009
US 2003166002	A1 Provisional	US 2001-339294P	20011212
		US 2002-267044	20021009
AU 2002340125	A1	AU 2002-340125	20021009
AU 2002340125	A8	AU 2002-340125	20021009

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2002340125	A1 Based on	WO 2003050237
AU 2002340125	A8 Based on	WO 2003050237

PRIORITY APPLN. INFO: US 2001-339294P 20011212; US 2002-267044 20021009

AN 2003-607827 [57] WPIDS

AB WO2003050237 A UPAB: 20030906
NOVELTY - Trisubstituted triazine library (A) is new.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) preparation of (A);

(2) synthesis of (A) with linker involving reacting (A) with a linker;

(3) triazine-linker compounds (B) comprising (A) bonded to the linker;

(4) affinity matrix beads (preferably agarose) comprising (B) loaded onto activated beads;

(5) a high density small molecule chip comprising a surface (preferably glass slide) onto which (B) are linked; and

(6) determination of binding affinity of proteins to several molecules involving incubating the high density small molecule chip with several labeled proteins and analyzing the labels to determine affinity of molecule for proteins.

USE - For preparing affinity matrix beads and for preparing high-density small molecule chips (claimed), which are useful in functional proteomics, sensors and study of genomes.

ADVANTAGE - The modification of (A) is highly flexible and hence generates diversity. The starting material and all of the required building blocks are relatively inexpensive, hence the preparation of (A) is simple. Byproducts are not generated during preparation, hence further purification is not required after cleavage of (A). The triazine library reduces the assay time from months to days and makes the chemical genetic approach more practical and efficient that the prior art.
Dwg.0/6

L29 ANSWER 3 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 2003-363111 [34] WPIDS
CROSS REFERENCE: 2003-354573 [33]
DOC. NO. CPI: C2003-201761
TITLE: Use of new and known aminoazetidine, pyrrolidine and piperidine derivatives for treating diseases related to histamine H3 receptor e.g. obesity, Alzheimer's disease and type 2 diabetes.
DERWENT CLASS: B02 B03
INVENTOR(S): DORWALD, F Z; HOHLWEG, R; DOERWALD, F Z
PATENT ASSIGNEE(S): (DORW-I) DORWALD F Z; (HOHL-I) HOHLWEG R; (BOEH) BOEHRINGER INGELHEIM INT GMBH; (NOVO) NOVO NORDISK AS
COUNTRY COUNT: 102
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 2003024928	A2	20030327	(200334)*	EN	27
RW: AT BE BG CH CY CZ DE DK EA EE ES FI FR GB GH GM GR IE IT KE LS LU MC MW MZ NL OA PT SD SE SK SL SZ TR TZ UG ZM ZW					
W: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW					
US 2003130253	A1	20030710	(200347)		
US 6673829	B2	20040106	(200411)		
EP 1430027	A2	20040623	(200441)	EN	
R: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LT LU LV MC MK NL PT RO SE SI SK TR					
AU 2002328796	A1	20030401	(200452)		
JP 2005510465	W	20050421	(200528)		53

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003024928	A2	WO 2002-DK593	20020911
US 2003130253	A1 Provisional	US 2002-383418P	20020521
		US 2002-242968	20020912
US 6673829	B2 Provisional	US 2002-383418P	20020521
		US 2002-242968	20020912
EP 1430027	A2	EP 2002-764566	20020911
		WO 2002-DK593	20020911
AU 2002328796	A1	AU 2002-328796	20020911
JP 2005510465	W	WO 2002-DK593	20020911
		JP 2003-528776	20020911

FILING DETAILS:

Searcher : Shears 571-272-2528

PATENT NO	KIND	PATENT NO
EP 1430027	A2 Based on	WO 2003024928
AU 2002328796	A1 Based on	WO 2003024928
JP 2005510465	W Based on	WO 2003024928

PRIORITY APPLN. INFO: DK 2002-750 20020516; DK 2001-1344 20010914
AN 2003-363111 [34] WPIDS
CR 2003-354573 [33]
AB WO2003024928 A UPAB: 20050504
NOVELTY - Aminoazetidine, pyrrolidine and piperidine derivatives (I) are used for the treatment of disorders and diseases related to the histamine H3 receptor.

DETAILED DESCRIPTION - Aminoazetidine, pyrrolidine and piperidine derivatives of formula (I), their diastereomers, enantiomers and/or tautomers or their salts are used for the treatment of disorders and diseases related to the histamine H3 receptor.

R1 = H, 1-8C alkyl, 3-8C alkenyl, 3-8C alkynyl, 3-7C cycloalkyl, 3-7C cycloalkenyl, 4-8C bicycloalkyl, 3-7C cycloalkyl-(1-3C) alkyl or (3-7C) cycloalkenyl-(1-3C) alkyl (all optionally substituted by at least one halo);
R2 = 1-6C alkyl;
X = (CH2)m-(Z)n-(CH2)o;
m, o = 0-4;
n = 0 or 1;
f = 0-2;
Z = O, NH, N(CH3), C(=O), CH(OH), C(=N-OH), S, S(=O), S(=O)2, CH=CH or C equivalent to C;
Y = 3-8C cycloalkyl or 5-8C cycloalkenyl (both optionally substituted by aryl or aryloxy (both optionally substituted by at least one halo, NO2, CN, OH, 1-6C alkanoyl, 1-6C alkylthio, 1-6C alkylsulfonyl, 1-6C alkyl, 1-6C alkoxy, 3-8C cycloalkyl, CF3, OCF3, NR7R8 or OCONR7R8 or 2 adjacent substituents form O-(CH2)1-3O), 1-6C alkyl, 1-6C alkoxy, 1-6C alkylthio, CN, CF3, OCF3 or halo), or aryl or heteroaryl (both optionally substituted by at least one halo, NO2, CN, OH, 1-6C alkanoyl, 1-6C alkylthio, 1-6C alkylsulfonyl, 1-6C alkyl, 1-6C alkoxy, 3-8C cycloalkyl, CF3, OCF3, NR3R4 or OCONR3R4 or 2 adjacent substituents form O-(CH2)1-3O, or aryl, aryloxy, aryl-1-6C alkyl or aryl-(1-6C) alkoxy (all optionally ring substituted by at least one halo, NO2, CN, OH, 1-6C alkanoyl, 1-6C alkylthio, 1-6C alkylsulfonyl, 1-6C alkyl, 1-6C alkoxy, 3-8C cycloalkyl, CF3, OCF3, NR5R6 or OCONR5R6 or 2 adjacent substituents form O-(CH2)1-3O)), and
R3-R8 = H, 1-6C alkyl, 3-8C cycloalkyl, 1-6C alkanoyl or aryl, or
NR3R4, NR5R6 and NR7R8 = 4-7 membered optionally saturated azetidinyl, pyrrolidinyl, piperidyl or azepanyl.

An INDEPENDENT CLAIM is included for new compounds of formula (I'), provided that:
(1) when m, n and o are 0, then R1 is not cyclopentyl, cyclohexyl, ethyl or methyl, and
(2) methyl-pyrrolidin-3-yl-**carbamic** acid 4-nitro-benzyl ester, 2-(2-(**4-chlorophenoxymethyl**)-1-methyl-1H-indol-3-yl)-N-methyl-N-(1-methyl-pyrrolidin-3-yl)-2-oxo-acetamide, N-butyl-2-(**4-chlorophenoxy**)-N-(1-ethyl-pyrrolidin-3-yl)-acetamide, 2-(2-(**4-chloro**-phenoxymethyl)-1-methyl-1H-indol-3-yl)-N-methyl-N-(1-methyl-**piperidin**-3-yl)-2-oxo-acetamide, 2-(1H-indol-3-yl)-N-(1-methylpiperidin-3-yl)-acetamide, 3-(1H-indol-3-yl)-N-(1-

methylpiperidin-3-yl)-propionamide and 2-(3,4-dichloro-phenyl)-N-methyl-N-(1-methyl-**piperidin**-3-yl)-acetamide are excluded.

Xa = (CH2)m-(Za)n-(CH2)o, and

Za = O, NH, N(CH3), C(=O), CH(OH), CH(O-(1-6C) alkyl), C(=N-OH), S, S(=O), S(=O)2, CH=CH or C equivalent to C.

ACTIVITY - Anorectic; Anabolic; Antidiabetic; Antiallergic; Antiinflammatory; Antiulcer; Nootropic; Neuroprotective; Tranquilizer; Antiemetic; Antiasthmatic; Antilipemic; Cardiant; Osteopathic; Antiarthritic; Auditory; Cytostatic.

MECHANISM OF ACTION - Histamine H3 receptor agonist; Histamine H3 receptor antagonist; Histamine H3 inverse agonist.

In a (35S)GTP gamma S assay, (I) exhibited IC50/EC50 values of less than 10 mu M, especially less than 500 nM for binding affinity to the human, monkey or rat histamine H3 receptor.

USE - Used for treating and/or preventing diseases and disorders related to H3 histamine receptor e.g. overweight or obesity, eating disorders (e.g. bulimia and binge eating), impaired glucose tolerance, type 2 diabetes, allergic rhinitis, ulcer, anorexia, Alzheimer's disease, narcolepsy and attention deficit disorder, for the delaying or preventing the progression from non-insulin requiring type 2 diabetes to insulin requiring type 2 diabetes, for reducing weight and suppressing appetite or satiety induction (all claimed). (I) Are also used for treating dementia, motion sickness, vertigo, irritable bowel syndrome, gall bladder disease, cancer of breast, prostate and colon, narcolepsy, attention deficit disorder, airway disorders (e.g. asthma), dyslipidemia, coronary heart disease and osteoarthritis.

ADVANTAGE - (I) Have high and selective binding affinity to the histamine H3 receptor.

Dwg.0/0

L29 ANSWER 4 OF 11 JAPIO (C) 2006 JPO on STN

ACCESSION NUMBER: 1993-058999 JAPIO
TITLE: CARBAMIC ACID DERIVATIVE AND ITS PRODUCTION
INVENTOR: TAKANO YASUO; TAKADOI MASANORI; HIRAYAMA TAKASHI; YAMANISHI MITSUHIRO
PATENT ASSIGNEE(S): KYORIN PHARMACEUT CO LTD
PATENT INFORMATION:

PATENT NO	KIND	DATE	ERA	MAIN IPC
JP 05058999	A	19930309	Heisei	C07D211-40

APPLICATION INFORMATION

STN FORMAT:	JP 1992-30071	19920121
ORIGINAL:	JP04030071	Heisei

PRIORITY APPLN. INFO.: JP 1991-31922 19910131
SOURCE: PATENT ABSTRACTS OF JAPAN (CD-ROM), Unexamined Applications, Vol. 1993

AN 1993-058999 JAPIO

AB PURPOSE: To efficiently obtain the subject derivative, having antiamnesic activity, effective in improving symptoms of Alzheimer type geriatric dementia, etc., having high safety and useful as an antidement agent, etc., by reacting a specific piperidine compound with an amino compound in the presence of a condensing agent.

CONSTITUTION: A compound expressed by formula I [Ar is (substituted) aromatic heterocyclic ring or (substituted)phenyl; X is S or 0] [e.g. 1-(4-pyridyl)-4- **piperidinol**] is dissolved in methylene chlormde, etc., and a compound expressed by formula II [R<SP>1</SP> is H or lower alkyl; R<SP>2</SP> is (substituted)lower alkyl,

(substituted) 7 phenyl, naphthyl, etc.] (e.g. N-methyl-**4-chloroaniline**) and a condensing agent (e.g. trichloromethyl chloroformate) are dropped and reacted with the above- mentioned compound expressed by formula I in the presence of triethylamine, etc., to afford the objective **carbamic** acid derivative expressed by formula III (Y s O or S) {e.g.[4-(1-(4-pyridyl)piperidyl)] N-methyl-**4-chlorophenylcarbamate**}.

L29 ANSWER 5 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 1983-747836 [35] WPIDS
DOC. NO. CPI: C1983-081878
TITLE: O-aryl N-oxalyl-N-methyl carbamate ester derivs. - useful as insecticides, acaricides and nematocides.
DERWENT CLASS: C02 C03 D22 E19
INVENTOR(S): BEHRENZ, W; HAMMANN, I; HEYWANG, G; HOMEYER, B; KUHLE, E
PATENT ASSIGNEE(S): (FARB) BAYER AG
COUNTRY COUNT: 23
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
DE 3205195	A	19830825	(198335)*		36
EP 87000	A	19830831	(198336)	GE	
R: AT BE CH DE FR GB IT LI NL SE					
AU 8311332	A	19830818	(198340)		
JP 58148805	A	19830905	(198341)		
DK 8300619	A	19831017	(198348)		
BR 8300748	A	19831116	(198402)		
ZA 8300949	A	19830920	(198405)		
PT 76182	A	19840223	(198412)		
HU 31971	T	19840628	(198430)		
DD 208536	A	19840404	(198431)		
ES 8404320	A	19840716	(198438)		
CS 8300955	A	19840917	(198501)		
US 4507292	A	19850326	(198515)		
EP 87000	B	19851113	(198546)	GE	
R: AT BE CH					
DE 3361189	G	19851219	(198601)		
IL 67880	A	19851129	(198602)		
US 4602033	A	19860722	(198632)		
CA 1242727	A	19881004	(198844)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
EP 87000	A	EP 1983-100864	19830131
ZA 8300949	A	ZA 1983-949	19830211
US 4507292	A	US 1983-461368	19830127
US 4602033	A	US 1985-688492	19850103

PRIORITY APPLN. INFO: DE 1982-3205195 19820213
AN 1983-747836 [35] WPIDS
AB DE 3205195 A UPAB: 19930925
Aryl carbamates of formula (I) are new

SCO.CO.N(CH3).COOR1 (I)

In (I), X is alkoxy, alkenoxy, alkynoxy, alkylthio, aryloxy or arylthio, all opt. substd., or NR3R4. R3 and R4 are each H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or aryl, all opt. substd., or together they complete an opt. substd. heterocycle. R1 is opt. substd. aryl.

Also new are the corresp. chlorides (II), where X is replaced by chloro.

(I) have insecticidal, acaricidal and nematocidal activities with low toxicity to warm-blooded animals and better activity than known N-carboxylated N-methylcarbamates. They can be used in agriculture, forestry, for protecting materials and in hygienic applications. (I) have excellent residual activity on wood and clay and are resistant to alkali on white-washed surfaces. (II) are intermediates for (I).

0/0

ABEQ EP 87000 B UPAB: 19930925

N-Oxalyl-N-methyl-**carbamic** acid aryl esters of the formula (I) in which R1 represents phenyl, 2-isopropylphenyl, 3-isopropylphenyl, 2-isopropoxyphenyl, 3,5-dimethyl-4-methyl-mercaptophenyl, 3-methyl-4-dimethylamino-phenyl, 4-nitrophenyl, 2-allyloxyphenyl, 3-sec.-butyl-4-methyl-phenyl, 4-methyl-3-isopropylphenyl, 2-dimethylaminophenyl, 2-(1',3'-di-oxolan-2-yl)-phenyl, 2-(4',5'-dimethyl-1',3'-dioxolan-2'-yl)-phenyl, naphth-1-yl, 4-(1,1-dimethyl-indanyl), 2,2-dimethyl-benzodioxolanyl or 2,2-dimethyl-2,3-dihydrobenzo-furanyl-(7) and represents methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec.-butoxy, tert.-butoxy, pentoxy, isopentoxy, hexoxy, isohexoxy, cyclopentoxy, cyclohexoxy, allyloxy, but-2-enyloxy, but-3-enyloxy, propargyloxy, but-2-inyloxy, but-3-inyloxy, 2-chloroethoxy, 2,2,2-trichloroethoxy, 2-fluoroethoxy, 2,2,2-trifluoroethoxy, 2-cyanoethoxy, 2-nitroethoxy, 2-methoxyethoxy, 2-di-methylaminoethoxy, phenoxy, **4-chlorophenoxy**, 4-methylphenoxy, 4-methoxyphenoxy, 4-di-methylaminophenoxy, 1-naphthoxy, 2-naphthoxy or methylthio, ethylthio, butylthio, phenylthio, **4-chlorophenylthio**, 4-methylphenylthio or amino, methylamino, dimethylamino, ethylamino, diethylamino, propylamino, isopropylamino, dipropylamino, diisopropylamino, butylamino, isobutylamino, dibutylamino, diisobutylamino, pyrrolidino, **piperidino**, morpholino, thiomorpholino, N-methylcyclohexylamino, N-phenylamino, N-methyl-N-phenylamino, diphenylamino, 4-methylphenylamino, N-methyl-N-4-methylphenylamino, N-methyl-N 4-methoxyphenylamino or N-methyl-N-**4-chlorophenylamino**.

ABEQ US 4507292 A UPAB: 19930925

Aryl N-oxalyl N-methylcarbamates of formula (I) are new. R' is phenyl, naphthyl, benzodioxolanyl, dihydrobenzofuranyl or indanyl. The last 3 radicals are attached via the aromatic ring thereof, the foregoing (sic) opt. being substd. by lower alkyl, lower alkenyl, lower alkynyl, lower alkoxy, lower alkenoxy, lower alkynoxy, lower alkylthio, lower alkenylthio, lower alkynylthio, di lower alkylamino, halo lower alkyl, halogen, NO2, CN, cyclo (lower alkyl), dioxanyl and/or dioxolanyl. X is NR3R4. R3 and R4 are H, 1-6C alkyl, 3-6C alkenyl, 3-6C alkynyl, 3-6C cycloalkyl or 4-6C cycloalkenyl, each of which is opt. substd. by halogen, CN, NO2, NH2, OH, lower alkoxy or di lower alkylamino, or represent a phenyl radical which is opt. substd. by 1-4C alkyl, halogen, CN, NO2, 1-4C alkoxy or 1-4C dialkylamine (sic); or R3 + R4 form (CH2)n, where n = 2-6, or (CH2)2-Y-(CH2)2 Y is O,S,SO or sulphone, or N.

USE - As arthropodicides and nematocides.

ABEQ US 4602033 A UPAB: 19930925

In (I) X is alkoxy, alkenoxy, alkynoxy, alkylthio, aryloxy or arylthio, all opt. substd. or NR3R4 R3 and R4 are each H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, or aryl all opt. substd, or together they complete an opt. substd. heterocycle. R1 is is opt. substd. aryl.

Also new are the corresp. chlorides (II), where X is replaced by chloro.

USE/ADVANTAGE - (I) have insecticidal, acaricidal and nematocidal activities with low toxicity to worm-blood animals and better activity then known N-carboxylated N-methylcarbamates.

They can be used in agriculture, forestry, for protecting materials and in hygienic applications. (I) have excellent residual activity on wood and clay and are resistant to alkali on white-washed surface. (II) are intermediates for (I).

L29 ANSWER 6 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
ACCESSION NUMBER: 1982-31696E [16] WPIDS
TITLE: Antidiarrhoeal **piperidine** butylamide derivative preparation - by reacting 4-(**4-chloro** phenyl)-1-(3,3-diphenyl-1-propyl) -4-**piperidinol** with di methyl **carbamic** acid halide and hydrolysing.
DERWENT CLASS: B02 C02
PATENT ASSIGNEE(S): (JANC) JANSSEN PHARM NV
COUNTRY COUNT: 1
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
JP 57042671	A	19820310	(198216)*		4
JP 63045382	B	19880909	(198840)		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
JP 57042671	A	JP 1980-114597	19800820

PRIORITY APPLN. INFO: JP 1980-114597 19800820
AN 1982-31696E [16] WPIDS
AB JP 57042671 A UPAB: 19930915
Production of 4-(4-chlorosoenyl) -4-hydroxy-N,N-dimethyl alpha,alpha-diphenyl-1 -piperidine-butaneamide and its acid addition salt, comprises reacting 4--(4-chlorophenyl)-1 (3,3-diphenyl -1-propyl)-4-piperidinol with dimethylcarbamic acid halide, hydrolysing product, and converting obtd. cpd. to acid addition salt.

The cpd. obtd. and known as loperamide is a useful antidiarrhoeal agent for humans and animals.

L29 ANSWER 7 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L29 ANSWER 8 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L29 ANSWER 9 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L29 ANSWER 10 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

L29 ANSWER 11 OF 11 WPIDS COPYRIGHT 2006 THE THOMSON CORP on STN
**** DATA NOT AVAILABLE FOR THIS ACCESSION NUMBER

=> fil hom
FILE 'HOME' ENTERED AT 17:07:54 ON 24 APR 2006

```
=> d que stat l2; d que stat l13; d his ful
L1                STR
```




```
REP G1=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1 N  AT  11
ECOUNT  IS E3 C  E1 N  E1 S  AT  13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13

STEREO ATTRIBUTES: NONE
L2          151 SEA FILE=REGISTRY SSS FUL L1

100.0% PROCESSED  176640 ITERATIONS                    151 ANSWERS
SEARCH TIME: 00.00.03



L8                STR
```




```
REP G1=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL  IS CLASS  AT  11 13
DEFAULT ECLEVEL IS LIMITED
ECOUNT  IS M1 N  AT  11
ECOUNT  IS E3 C  E1 N  E1 S  AT  13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS  13
```

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L10 42 SEA FILE=MARPAT SSS FUL L8 (MODIFIED ATTRIBUTES)
L11 STR



REP G1=(1-2) C
REP G2=(1-2) C
REP G3=(1-2) C
VPA 13-1/2/4/5/6 U
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
MLEVEL IS CLASS AT 13
DEFAULT ECLEVEL IS LIMITED
ECOUNT IS E3 C E1 N E1 S AT 13

GRAPH ATTRIBUTES:
RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 16

STEREO ATTRIBUTES: NONE

ATTRIBUTES SPECIFIED AT SEARCH-TIME:
ECLEVEL IS LIM ON ALL NODES
ALL RING(S) ARE ISOLATED

L12 12 SEA FILE=MARPAT SUB=L10 SSS FUL L11 (MODIFIED ATTRIBUTES)
L13 9 SEA FILE=MARPAT ABB=ON PLU=ON L12/COMPLETE

(FILE 'CAPLUS' ENTERED AT 16:52:37 ON 24 APR 2006)
DEL HIS Y

FILE 'REGISTRY' ENTERED AT 16:53:19 ON 24 APR 2006
ACT GEMB5234/A

L1 STR
L2 151 SEA SSS FUL L1

FILE 'REGISTRY' ENTERED AT 16:53:37 ON 24 APR 2006
D QUE STAT

FILE 'CAPLUS' ENTERED AT 16:53:37 ON 24 APR 2006

```
L3              4 SEA ABB=ON  PLU=ON  L2
L4              2 SEA ABB=ON  PLU=ON  L3 NOT (PY=>2002 OR PD=>20020806)
                  SEL HIT L4 1-2 RN
                  D L4 1-2 IBIB ABS HITSTR

     FILE 'CAOLD' ENTERED AT 16:54:30 ON 24 APR 2006
L5              0 SEA ABB=ON  PLU=ON  L2

     FILE 'USPATFULL' ENTERED AT 16:54:35 ON 24 APR 2006
L6              3 SEA ABB=ON  PLU=ON  L2
                  D 1-3 IBIB ABS

     FILE 'MEDLINE, BIOSIS, EMBASE' ENTERED AT 16:54:49 ON 24 APR 2006
L7              0 SEA ABB=ON  PLU=ON  L2

     FILE 'MARPAT' ENTERED AT 16:54:55 ON 24 APR 2006
L8                STR L1
L9              1 SEA SSS SAM L8 (MODIFIED ATTRIBUTES)
L10            42 SEA SSS FUL L8 (MODIFIED ATTRIBUTES)
L11               STR L8
L12            12 SEA SUB=L10 SSS FUL L11 (MODIFIED ATTRIBUTES)
L13             9 SEA ABB=ON  PLU=ON  L12/COMPLETE
                  D QUE STAT
                  D L13 1-9 .BEVMAR1

     FILE 'REGISTRY' ENTERED AT 16:59:28 ON 24 APR 2006
L14        315199 SEA ABB=ON  PLU=ON  ?CARBAMIC ACID?/CNS
L15        936652 SEA ABB=ON  PLU=ON  ?PIPERIDIN?/CNS
L16         17659 SEA ABB=ON  PLU=ON  L14(L)L15
L17       1147742 SEA ABB=ON  PLU=ON  ?THIAZOL?/CNS
L18           567 SEA ABB=ON  PLU=ON  L16(L)L17
                  D KWIC
L19       4274872 SEA ABB=ON  PLU=ON  ?CHLORO?/CNS
L20            61 SEA ABB=ON  PLU=ON  L18(L)L19
                  D KWIC

     FILE 'CAPLUS' ENTERED AT 17:01:05 ON 24 APR 2006
L21            21 SEA ABB=ON  PLU=ON  L20
L22           199 SEA ABB=ON  PLU=ON  (4(W)(CL OR CHLORO?))(S)CARBAMIC
L23            11 SEA ABB=ON  PLU=ON  L22(S)PIPERIDIN?
                  D KWIC
                  D KWIC 2
L24            32 SEA ABB=ON  PLU=ON  (L21 OR L23) NOT L4
L25             8 SEA ABB=ON  PLU=ON  L24 NOT (PY=>2002 OR PD=>20020806)
                  D 1-8 .BEVSTR

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 17:03:31 ON 24 APR 2006
L26             5 SEA ABB=ON  PLU=ON  L20
L*** DEL        5 DUP REM L26 (0 DUPLICATES REMOVED)
                  D 1-5 IBIB ABS

     FILE 'HOME' ENTERED AT 17:04:13 ON 24 APR 2006

     FILE 'WPIDS' ENTERED AT 17:04:31 ON 24 APR 2006
L*** DEL        5 S L20

     FILE 'MEDLINE, BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH,
     JICST-EPLUS, JAPIO' ENTERED AT 17:05:32 ON 24 APR 2006
```

```
L27           6 SEA ABB=ON  PLU=ON  L23
L28          11 SEA ABB=ON  PLU=ON  L26 OR L27
L29          11 DUP REM L28 (0 DUPLICATES REMOVED)
                D 1-11 IBIB ABS

     FILE 'HOME' ENTERED AT 17:06:42 ON 24 APR 2006

     FILE 'WPIDS' ENTERED AT 17:06:57 ON 24 APR 2006
L30           5 SEA ABB=ON  PLU=ON  L18(L)L19
                D 1-5 IBIB ABS

     FILE 'HOME' ENTERED AT 17:07:54 ON 24 APR 2006
                D QUE STAT L2
                D QUE STAT L13


     FILE REGISTRY
     Property values tagged with IC are from the ZIC/VINITI data file
     provided by InfoChem.

     STRUCTURE FILE UPDATES:   23 APR 2006  HIGHEST RN 881543-45-9
     DICTIONARY FILE UPDATES:  23 APR 2006  HIGHEST RN 881543-45-9

     New CAS Information Use Policies, enter HELP USAGETERMS for details.

     TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

       Please note that search-term pricing does apply when
       conducting SmartSELECT searches.

     ************************************************************
     *                                                          *
     * The CA roles and document type information have been removed from *
     * the IDE default display format and the ED field has been added,   *
     * effective March 20, 2005.  A new display format, IDERL, is now    *
     * available and contains the CA role and document type information. *
     *                                                          *
     ************************************************************

     Structure search iteration limits have been increased.  See HELP SLIMI
     for details.

     REGISTRY includes numerically searchable data for experimental and
     predicted properties as well as tags indicating availability of
     experimental property data in the original document.  For information
     on property searching in REGISTRY, refer to:

     http://www.cas.org/ONLINE/UG/regprops.html

     FILE CAPLUS

     Copyright of the articles to which records in this database refer is
     held by the publishers listed in the PUBLISHER (PB) field (available
     for records published or updated in Chemical Abstracts after December
     26, 1996), unless otherwise indicated in the original publications.
     The CA Lexicon is the copyrighted intellectual property of the
     American Chemical Society and is provided to assist you in searching
     databases on STN.  Any dissemination, distribution, copying, or storin
     of this information, without the prior written consent of CAS, is
```

strictly prohibited.

FILE COVERS 1907 - 24 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 23 Apr 2006 (20060423/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply
They are available for your review at:

http://www.cas.org/infopolicy.html

FILE CAOLD
FILE COVERS 1907-1966
FILE LAST UPDATED: 01 May 1997 (19970501/UP)

This file contains CAS Registry Numbers for easy and accurate substance identification. Title keywords, authors, patent assignees, and patent information, e.g., patent numbers, are now searchable from 1907-1966. TIFF images of CA abstracts printed between 1907-1966 are available in the PAGE display formats.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

FILE USPATFULL
FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Apr 2006 (20060420/PD)
FILE LAST UPDATED: 20 Apr 2006 (20060420/ED)
HIGHEST GRANTED PATENT NUMBER: US7032245
HIGHEST APPLICATION PUBLICATION NUMBER: US2006085880
CA INDEXING IS CURRENT THROUGH 20 Apr 2006 (20060420/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Apr 2006 (20060420/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006

FILE MEDLINE
FILE LAST UPDATED: 22 APR 2006 (20060422/UP). FILE COVERS 1950 TO DA

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.ht
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Searcher : Shears 571-272-2528

FILE BIOSIS
FILE COVERS 1969 TO DATE.
CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT
FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 19 April 2006 (20060419/ED)

FILE EMBASE
FILE COVERS 1974 TO 24 Apr 2006 (20060424/ED)

EMBASE has been reloaded. Enter HELP RLOAD for details.

EMBASE is now updated daily. SDI frequency remains weekly (default) and biweekly.

This file contains CAS Registry Numbers for easy and accurate substance identification.

FILE MARPAT
FILE CONTENT: 1961-PRESENT VOL 144 ISS 16 (20060421/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US 2006035965 16 FEB 2006
DE 102005008856 09 FEB 2006
EP 1624071 08 FEB 2006
JP 2006050780 16 FEB 2006
WO 2006026533 09 MAR 2006
GB 2416167 18 JAN 2006
FR 2874024 10 FEB 2006
RU 2269538 10 FEB 2006
CA 2512063 14 JAN 2006

Expanded G-group definition display now available.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

FILE WPIDS
FILE LAST UPDATED: 21 APR 2006 <20060421/UP>
MOST RECENT DERWENT UPDATE: 200626 <200626/DW>
DERWENT WORLD PATENTS INDEX SUBSCRIBER FILE, COVERS 1963 TO DATE

>>> FOR A COPY OF THE DERWENT WORLD PATENTS INDEX STN USER GUIDE, PLEASE VISIT:
http://www.stn-international.de/training_center/patents/stn_guide.pdf

>>> FOR DETAILS OF THE PATENTS COVERED IN CURRENT UPDATES, SEE
http://scientific.thomson.com/support/patents/coverage/latestupdates/

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html a
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

Searcher : Shears 571-272-2528

>>> UPCOMING NEW DWPI: EFFECTS ON SCRIPT RUNS - SEE NEWS MESSAGE <<<

FILE CONFSCI
FILE COVERS 1973 TO 10 Apr 2006 (20060410/ED)

CSA has resumed updates, see NEWS FILE

FILE SCISEARCH

FILE COVERS 1974 TO 20 Apr 2006 (20060420/ED)

SCISEARCH has been reloaded, see HELP RLOAD for details.

FILE JICST-EPLUS
FILE COVERS 1985 TO 24 APR 2006 (20060424/ED)

THE JICST-EPLUS FILE HAS BEEN RELOADED TO REFLECT THE 1999 CONTROLLED TERM (/CT) THESAURUS RELOAD.

FILE JAPIO
FILE LAST UPDATED: 3 APR 2006 <20060403/UP>
FILE COVERS APRIL 1973 TO DECEMBER 22, 2005

>>> GRAPHIC IMAGES AVAILABLE <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOT YET AVAILABLE IN THIS FILE.
USE IPC7 FORMAT FOR SEARCHING THE IPC. WATCH THIS SPACE FOR FURTHE
DEVELOPMENTS AND SEE OUR NEWS SECTION FOR FURTHER INFORMATION
ABOUT THE IPC REFORM <<<

FILE HOME